skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy

Review

(2613) Views  (1026) Full article downloads

Authors: Aarat M Patel, Larry W Moreland

Published Date October 2010 Volume 2010:4 Pages 263 - 278
DOI: http://dx.doi.org/10.2147/DDDT.S14099

Aarat M Patel1,2, Larry W Moreland1
1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA; 2Division of Pediatric Rheumatology, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

Abstract: The dawn of the biologic era has been an exciting period for clinical research and patient care in rheumatoid arthritis (RA). Targeted biologic therapies have changed the outcome of this disease and made remission a realistic outcome for many patients. Tocilizumab (TCZ, Actemra®), is a humanized monoclonal antibody against the interleukin 6 receptor and has been approved in many countries for the treatment of moderate to severe RA. There have been a number of important clinical trials demonstrating the efficacy of TCZ in active rheumatoid arthritis. This review summarizes the data on efficacy, patient-reported outcomes, adverse events, and safety from some of these trials. Current trends in clinical practice will be discussed. It is difficult to place TCZ and many new medications in the algorithm of treatment at present. However, the next few years will hopefully reveal their role as we better define abnormal immune processes in individuals with RA.

Keywords: tocilizumab, rheumatoid arthritis, interleukin-6, biologics






Readers of this article also read:

Pharmacological control of neutrophil-mediated inflammation: Strategies targeting calcium handling by activated polymorphonuclear leukocytes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Recent advances in neutralizing the IL-6 pathway in arthritis
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
Development of oral immunomodulatory agents in the management of multiple sclerosis
Primary care for diabetes mellitus: perspective from older patients
Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University